Compare
Cryoport, Inc. vs Lifevantage Corp vs Anaptysbio, Inc vs Keros Therapeutics, Inc.
| Latest fiscal year | Cryoport, Inc. CYRX | Lifevantage Corp LFVN | Anaptysbio, Inc ANAB | Keros Therapeutics, Inc. KROS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $176.18M | $182.59M | $234.60M | $244.06M |
| Revenue growth (YoY) | +12.4% | -20.1% | +157.0% | n/m |
| Gross margin | 47.1% | 77.6% | n/a | n/a |
| Operating margin | -20.9% | 3.3% | 20.4% | 27.7% |
| Net margin | 44.4% | 2.8% | -5.6% | 35.7% |
| Net income | $78.30M | $5.07M | -$13.23M | $87.01M |
| EPS (Diluted) | $1.40 | $0.40 | -$0.46 | $2.30 |
| Operating cash flow | -$8.58M | $10.24M | $19.70M | $107.50M |
| Free cash flow | -$25.02M | $6.67M | $19.61M | $105.95M |
| Cash & equivalents | $250.49M | n/a | $238.20M | $287.42M |
| Total assets | $764.99M | $62.11M | $364.39M | $338.02M |
| Total liabilities | $262.35M | $28.52M | n/a | $34.89M |
| Shareholders' equity | $502.64M | $33.59M | $37.21M | $303.13M |
| Return on year-end equity | 15.6% | 15.1% | -35.6% | 28.7% |
| Shares outstanding | 49.85M | 12.52M | 28.02M | 19.54M |
Revenue, most recent five fiscal years
| Fiscal year | Cryoport, Inc. | Lifevantage Corp | Anaptysbio, Inc | Keros Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $176.18M Ended 2025-12-31 | $182.59M Ended 2026-06-30 | $234.60M Ended 2025-12-31 | $244.06M Ended 2025-12-31 |
| 1 year earlier | $156.77M Ended 2024-12-31 | $228.53M Ended 2025-06-30 | $91.28M Ended 2024-12-31 | $3.55M Ended 2024-12-31 |
| 2 years earlier | $168.66M Ended 2023-12-31 | $200.16M Ended 2024-06-30 | $17.16M Ended 2023-12-31 | $151.0K Ended 2023-12-31 |
| 3 years earlier | $237.28M Ended 2022-12-31 | $213.40M Ended 2023-06-30 | $10.29M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | $222.61M Ended 2021-12-31 | $206.36M Ended 2022-06-30 | $63.17M Ended 2021-12-31 | $20.10M Ended 2021-12-31 |